Moreover, Vaccibody has compelling preclinical data in a range of animal models within cancer and infectious diseases including Vaccines against Melanoma, Prostate Cancer, B Cell Lymphoma, Multiple Myeloma, Influenza, Herpes Simplex Virus 2, HIV, Ebola and Tuberculosis. In all studies performed, the Vaccibody Vaccine Targeting Platform Technology has shown better results than any of the comparators tested at much lower vaccine doses.
Vaccibody’s studies in animal models within cancer and infectious diseases form a strong basis for developing Vaccibody’s for veterinary use. Vaccibody AS is currently partner in a Horizon2020 Project for the Development of Vaccines against PRRSV in swine and a BIOTEK2021 NFR Project for the Development of Vaccines for the Fish Industry. Vaccibody has signed an industrial licensing agreement with a veterinary vaccine company for utilization of the Vaccibody technology for poultry vaccines.